19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace.

SCAMHC serves all individuals regardless of inability to pay. Discounts for essential services are offered based on family size and income. For more information, contact (334) 222-2523 or our 24/7 Helpline at 1-877-530-0002.

 

 


powered by centersite dot net
Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
Many Marijuana Vendors Aim Advertising at Kids: StudyHeart Function Rebounds for Kids With COVID-Linked MIS-CWhich Kids Are Most Vulnerable to Severe COVID-19?At-Home COVID Tests Accurate for Ki​ds: StudyCDC Study Shows Power of Flu Vaccine for KidsCOVID Hospitalizations Rising in Kids Too Young for VaccineNearly 600,000 U.S. Kids Had COVID Last WeekWhite House to Give Schools 10 Million Free COVID Tests Every MonthKids' Behavior Worsened With Remote Learning: StudyLater School Start Times Boost Parents' Health, TooUrban Air Pollution Drives Millions of Cases of Asthma in KidsCDC Backs Boosters for High-Risk Kids Aged 5-11, Shorter Time Between ShotsA Better Way to Correct Severe Scoliosis in Kids?Getting Your Child Their Vaccine?  Some Tips on Easing Needle FearsU.S. Hospitals Seeing Record Numbers of Young COVID PatientsSevere Illness in Children Brings Hardship for FamiliesReal-World Data Confirms Pfizer Vaccine Safe for Kids Ages 5-11Family Factors Affect Child's Odds for Cleft PalateAs Omicron Spreads, Child Hospitalizations Climb 30% in Past WeekNew Clues to Sudden Unexplained Deaths in Young KidsSevere Illness in a Child Takes Big Toll on Parents, Siblings: StudyProgram Aims to Get Lifesaving Drugs to Kids With Cancer in Poorer CountriesSchool COVID Outbreaks Drop When Adults Wear Masks, Study FindsMany Overweight Kids Already Have Hardened Arteries, DiabetesCDC Supports 'Test-to-Stay' Strategy for SchoolsJunk Food Ads Reaching Kids Through Livestream Gaming PlatformsWhat Does 'Long COVID' Look Like in Kids?New Drug a Good Treatment Option for Severe Asthma in KidsFebrile Seizures: How to Protect Your ChildNew Treatment Greatly Boosts Survival for Kids With a Rare, Aggressive CancerRisk of Vision Trouble Rises in Children With Type 2 DiabetesMore Time Outdoors May Lower Risk of MS in YouthNew Asthma Drug Helps Kids, But Price Tag Is HighUS Surgeon General Report Warns of Mental Health Crisis Hitting YouthAnother Benefit to Asthma Control for Kids: Less Bullying1 in 3 U.S. Children Lack Adequate Health InsuranceWhat's Behind Unexplained Epilepsy in Kids? A Gene Test May TellIs the Mumps Vaccine Becoming Less Effective?Autism Now Diagnosed in 1 in Every 44 Children, CDC SaysKids With Uncontrolled Asthma at Higher Odds for Severe COVID-19Nearly 7% of U.S. Kids Have Had a Head Injury or ConcussionAre Your Holiday Gifts on the 'Noisy Toy List'?Many Kids, Teens Think Girls Don't Care About Computer ScienceMost Parents Say Their Kids Aren't Thankful Enough: PollPandemic Curbed Kids' Efforts to Lose Excess WeightClimate Change May Not Increase Allergies in Kids With Asthma: StudyNearly 10% of Younger Kids Have Gotten First COVID Vaccine DoseAHA News: Family-Based Programs Targeting Childhood Obesity Can Be Good for Parents, TooCases of Children's Severe COVID-Linked Illness Were Worse in Second WaveFace Masks Don't Hide Emotions From Kids: Study
Questions and AnswersVideosLinksBook Reviews
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Parenting

New Drug a Good Treatment Option for Severe Asthma in Kids

HealthDay News
by By Ernie Mundell and Robert Preidt HealthDay Reporters
Updated: Dec 13th 2021

new article illustration

MONDAY, Dec. 13, 2021 (HealthDay News) -- Parents of children with moderate-to-severe asthma may have a much-needed treatment option: A new trial finds that an injected monoclonal antibody drug called dupilumab significantly reduces a child's odds of serious asthma attacks and improves lung function.

“We were not surprised, because dupilumab was very effective in clinical trials in adults and adolescents, but we were delighted with the results and the hope they bring to children and their families," said trial lead investigator Dr. Leonard Bacharier. He's an asthma specialist at Monroe Carell Jr. Children’s Hospital, part of Vanderbilt University Medical Center in Nashville, Tenn.

One expert who wasn't connected to the trial was encouraged by the findings, calling them "very exciting."

"I am especially impressed with the study design, which combines patient-reported outcomes with markers of lung function," explained Dr. Michael Grosso, chief medical officer and chair of pediatrics at Huntington Hospital, in Huntington, N.Y. That the drug "was found to be effective both ways – in how patients feel and how their lungs are working -- is very important," he said.

Dupilumab (Dupixent) received U.S. Food and Drug Administration approval for use in children ages 6-11 in October. The biologic drug targets type 2 inflammation in asthma and has been approved for the treatment of asthma in adults and adolescents for several years. The new study was funded by Sanofi and Regeneron Pharmaceuticals, which make dupilumab.

Asthma is the most common chronic disorder of childhood and affects more than 5 million children younger than 18, according to the U.S. Centers for Disease Control and Prevention.

The phase 3 clinical trial involved more than 400 children ages 6-11 with uncontrolled moderate-to-severe asthma. It found the drug to be highly effective.

In the study, the children received dupilumab or a placebo in addition to their standard therapy every two weeks for a year.

Most of the children in the study had type 2 inflammation. Among those kids, the rate of severe asthma attacks -- those requiring steroid treatment, emergency care or hospitalization -- was nearly 60% lower among those who received dupilumab versus those who hadn't, Bacharier's group reported.

Children with type 2 inflammation who received the drug also had improved lung function and improved asthma control.

Dupilumab was not effective for children who did not have type 2 inflammation, according to the findings, which were published Dec. 9 in the New England Journal of Medicine.

“This is the first study of its kind in children ages 6 to 11 that has demonstrated that a biologic improves asthma exacerbations, lung function and asthma control,” Bacharier said in a Vanderbilt University Medical Center news release.

The drug was safe and very few children had to stop taking it due to negative side effects, according to the researchers.

“This is a really important advance for children with moderate-to-severe asthma and their families,” Bacharier said.

Asthma is a leading cause of hospitalization for children, and children with moderate-to-severe asthma may have reduced lung function and be at greater risk for lung diseases in adulthood, the researchers explained.

“As asthma gets increasingly severe, the burden becomes substantial, impacting the child and the entire family,” Bacharier said. “While we have very good asthma therapies available, none of them are perfect in eliminating severe exacerbations.”

Dr. Sherry Farzan is an allergist at Northwell health in Great Neck, N.Y., and served as a clinical investigator on the new trial. She believes dupilumab could be "a game changer for patients with moderate-to-severe asthma, whose lives are marked by hospitalizations, ER visits, frequent symptoms, and limitations to physical activity."

For his part, Grosso noted that "most children with asthma don’t have the disease severity for which this drug was tested."

But he agreed with Farzan that "the minority with moderate-to-severe asthma not controlled with standard treatments could really benefit from an effective biological [like dupilumab]."

More information

The American Lung Association has more on childhood asthma.


SOURCES: Michael Grosso, M.D., chief medical officer and chair, pediatrics, Huntington Hospital, Long Island, N.Y.; Sherry Farzan, MD, allergist, Northwell Health, Great Neck, N.Y.; Vanderbilt University Medical Center, news release, Dec. 8, 2021